Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
12
Number of overlapping holdings
24.0%
% of FTXH's 51 holdings also in CANC
25.0%
% of CANC's 48 holdings also in FTXH
Overlap by Weight
Sector Drift (FTXH minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in FTXH |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
BRISTOL-MYERS SQUIBB CO | 7.0% | 4.0% | 4.0% |
|
ELI LILLY & CO | 3.9% | 5.4% | 3.9% |
|
AMGEN INC | 3.8% | 2.8% | 2.8% |
|
MERCK & CO. INC. | 7.1% | 2.7% | 2.7% |
|
EXELIXIS INC | 2.1% | 3.8% | 2.1% |
Position Highlights (Non-Overlapping Exposures)
FTXH Overweight Relative to CANC
|
JOHNSON & JOHNSON | 8.1% |
|
PFIZER INC | 7.1% |
|
ABBVIE INC | 5.1% |
|
MERCK & CO. INC. | 4.5% |
|
UNITED THERAPEUTICS CORP | 3.8% |
|
ZOETIS INC | 3.8% |
|
BIOGEN IDEC INC | 3.6% |
|
VIATRIS, INC. | 3.5% |
|
BRISTOL-MYERS SQUIBB CO | 3.0% |
 |
JAZZ PHARMACEUTICALS PLC | 3.0% |
FTXH Underweight Relative to CANC
|
REVOLUTION MEDICINES, INC. | -5.7% |
 |
ROCHE HOLDINGS LTD-SPONS ADR | -5.1% |
|
BRIDGEBIO PHARMA, INC. | -4.5% |
|
NOVARTIS AG | -4.3% |
 |
ASTRAZENECA PLC | -4.2% |
|
NUVALENT, INC. CLASS A | -3.9% |
|
SUMMIT THERAPEUTICS INC | -3.9% |
 |
GENMAB A/S SPONSORED ADR | -3.4% |
 |
MERUS N.V. | -3.2% |
 |
ZAI LAB LTD. UNSPONSORED ADR | -3.0% |